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Abstract
Background: As reported by increasing literature, a significant number of
patients with SARS-CoV-2 infection developed smell/taste disorders. Aim of
this study is to determine the prevalence and severity of these symptoms
among laboratory-confirmed SARS-CoV-2 patients. Secondary objective is to
determine their onset/recovery time.
Methods: This cross-sectional study was conducted from March 10 to
30, 2020 at Novara University Hospital during the COVID-19 Italian outbreak.
The 355 enrolled patients answered a questionnaire at 14th (or more) days
after proven infection.
Results: The overall population prevalence of both smell/taste or one of the
two disorders was 70%. They were first symptoms in 31 (8,7%) patients. Most
patients reported a complete loss that in half of the cases (49.5%) was fully
recovered after 14 days, with a median recovery time of 10 days.
Conclusion: This study confirms a high prevalence of smell/taste disorders in
COVID-19 infection with self-recovery for half cases after about 2 weeks.
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1 | INTRODUCTION
Anosmia and hyposmia, the inability to perceive smells
and a reduced or altered ability respectively, as well as
taste perception alterations, are occasionally associated
with respiratory virus infection, including the well-
known family of coronavirus.1 Since mid-February 2020,
SARS-CoV-2, a novel coronavirus initially identified in
late 2019 in China,2 spread worldwide. As the infection
was better characterized, the main symptoms of fever,
cough, tiredness, and difficulty breathing were well-char-
acterized.3 However several anecdotal case reports,4,5
case series,6-8 and surveys 9-13 suggested that a significant
amount of patients with suspected Sars-CoV-2 infection
also developed anosmia/hyposmia and/or taste alter-
ation, and in a relevant amount of patients, these were
the first symptoms of COVID-19. Most of these studies,
however, base their results on presumptive or symptoms
based COVID-19 diagnosis. Only one study to date have
assessed a population of laboratory-confirmed patients,
performing quantitative smell assessment, but without
investigating taste.14
Limited knowledge is available on prevalence, sever-
ity, and recovery time of these disorders in SARS-CoV-2
patients.
The aim of this study was to investigate the preva-
lence and severity of smell and taste disorders in a popu-
lation of laboratory-confirmed SARS-CoV-2 patients.All authors equal contribute to this paper.
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A secondary objective was to investigate the onset and
recovery time from the same symptoms.
2 | MATERIALS AND METHODS
This is a cross-sectional study conducted from March
10 to 30, 2020 at the ENT clinic of the University of East-
ern Piedmont, Ospedale Maggiore della Carità in Novara,
Italy. The study was carried out in accordance with the
ethical standards of the Helsinki Declaration and was
approved by the local ethical review board (Comitato
Etico Interaziendale n.88/2020).
The study included a convenience sample of SARS-
CoV-2 polymerase chain reaction (PCR) confirmed cases
being admitted for care or assessed and discharged dur-
ing the study period.
Patients with confirmed SARS-CoV-2 infection were
prospectively identified and recorded.
Administrative data were extracted from hospital
databases and patients were offered a follow-up inter-
view. Patients were informed about the study and
asked to participate at the time of the follow-up inter-
view (= or > 14 days from diagnosis). Interviews were
carried out by two attending physicians either in
person or by phone using a structured questionnaire.
Inclusion criteria were: Age > 18-year old, informed
consent and laboratory proven SARS-CoV-2 infection
with a mild or moderate presentation of COVID-19
according to the severity classification of the Massa-
chusetts General Hospital COVID-19 treatment
guidance.15
Exclusion criteria were: declined informed consent, a
severe form of COVID-19.
Interview data were anonymously collected and no
reward was offered for participation.
The questionnaire consisted of 22 questions,
including general demographic information (age,
gender), medical history (comorbidities, risks factors),
SARS-CoV-2 related questions (risk exposure for occu-
pational/family reasons, duration of infection,
symptoms—fever, cough, dyspnea, fatigue or muscle
pain, diarrhea or nausea) and specific information
about the sense of smell and about taste (presence/
absence, 0 to 10 numeric rating scale [NRS] of smell at
baseline, during infection, after 14 days and at answer-
ing time—were 0 is “no sense of smell/taste” and 10 is
“normal sense of smell/taste”, time of onset/recovery).
The survey is available in the supplementary online
material (Data S1). A clinically significant change in
the smell of taste perception was defined as having a
score difference equal to or greater than two points
between study times.
2.1 | Statistical analysis
Smell and taste assessment were reported using data
from the scales which have been treated as quantitative
real values. Categorical variables were reported as a
proportion while quantitative variables as median and
([25-75 quartile] range) where appropriate. Compari-
son of the baseline, worst, and 14-days smell and taste
perception was performed using Friedman's test. All
statistical analysis has been performed using R 3.6.3,
(R Core Team [2020]. R: A language and environment
for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria). A P-value <.05 was con-
sidered significant.
3 | RESULTS
We interviewed a total of 355 patients with laboratory-
confirmed diagnosis of SARS-CoV-2. The population had
a median time from symptoms onset of 23 ([17-28] range
2-53) days. The median age was 50 years old, 192 (54%)
were male. The overall population prevalence of both
smell and taste or either one of the two disorders was
70% (249 of 355). Among the two study symptoms,
14 (3.9%) patients presented a smell disorder with no
alteration of taste, while 12 (3.4%) patients presented
with a taste disorder with no alternation of smell (but
presented other SARS-CoV-2 systemic symptoms). Two
patients presented with smell disorders as the sole SARS-
CoV-2 symptom, while none had taste disorders as their
only symptom. Smell or taste disorders were the first
symptom of presentation in 31 (8.7% of entire population
and 13.0%) patients. Patients characteristics of the inter-
viewed population, and for those presenting with olfac-
tory and taste dysfunctions are presented in Table 1.
3.1 | Smell disorders
Two hundred and thirty-seven 237 (66%) patients
reported a change in smell perception greater than two
points between their baseline smell and the worst smell
experienced during the infection. Of these, 128 (54%)
reported the smell dysfunction already present at the
time of diagnosis.
These patients had a baseline smell perception of
10 ([9, 10] range 3-10) with the worst smell perception
during the infection of 0 ([0-2] range 0-7). At 14 days
from infection 115 (49.5%) of patients declared a full
recovery with smell as good as at baseline, while the
remaining 122 declared a certain degree of remaining
deficit with an overall population perception of
1592 DELL’ERA ET AL.
8 ([6–10] range 0-10). Variation of smell perception at
different study period is presented in Figure 1A. One
hundred and forty-nine (62.9%) patients reported full
recovery at the time of the interview, with a median
recovery time of 10 ([7–15] range 1-25) days. No patient
reported taking any specific therapy for their disorder.
TABLE 1 Characteristics of patients with SARS-CoV-2 infection included in the study
Overall population (n = 355) Olfactory symptoms (n = 237) Taste symptoms (n = 232)
Prevalence (%) 70% 66% 65.4%
Age (years), median [IQR] 50 [40-59.5] 49 [40-60] 51 [51-60]
Female, n (%) 163 (45.9) 115 (48.5) 110 (47.4)
Smoker, n (%) 48 (13.5) 32 (13.5) 32 (13.8)
Specific risk factors, n (%)
Health care provider 174 (49) 109 (52.7) 101 (43.5)
Close contact 174 (49) 125 (46) 120 (51.7)
Comorbidities, n (%)
Cardiac 42 (11.8) 31 (8.7) 30 (12.9)
Respiratory 40 (11.3) 30 (8.5) 30 (12.9)
Allergic/nasosinusal 38 (10.7) 26 (7.3) 23 (9.9)
Other symptoms, n (%)
Fever 256 (72.1) 181 (76.4) 181 (78)
Cough 170 (47.9) 126 (53.2) 125 (53.9)
Fatigue 143 (40.3) 104 (43.9) 95 (40.9)
Dyspnea 77 (21.7) 50 (21.1) 54 (23.3)
Diarrhea 70 (19.7) 47 (19.8) 48 (20.7)
FIGURE 1 Smell, A, and taste, B, perception (score) before developing symptoms (baseline), at the highest intensity of symptoms
(worst) and after 2 weeks from their onset (14 days)
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3.2 | Taste disorders
Two hundred and thirty-two (65.4%) patients reported a
change in taste perception greater than two points between
their baseline taste and the worst test experienced during
the infection. These patients had a baseline taste perception
of 10 ([9, 10] range 5-10) with the worst taste perception
during the infection of 0 ([0-2] range 0-10). At 14 days from
infection 117 (50.4%) of patients declared a full recovery
with the test as good as at baseline while the remaining
115 (49.6%) declared a certain degree of remaining deficit
with an overall population perception of 8 ([6–10] range
0-10). Variation of taste perception at different study period
is presented in Figure 1B. One hundred and forty-eight
(63.8%) patients reported full recovery at the time of the
interview, with a median recovery time of 10 ([7–15] range
2-25) days. No patient reported taking any specific therapy
for their taste disorder.
Figure 2 shows the daily rate of recovery for both
smell and taste disorders.
4 | DISCUSSION
Over the last weeks, an increasing number of authors
reported a high rate of olfactory and gustatory dysfunc-
tions in COVID-19 patients, sometimes presenting as the
first symptom.4-14
The main goal of the present study was to evaluate the
prevalence of smell/taste disorders in a large COVID-19
positive population, composed of patients who were
either asymptomatic or presenting mild or moderate
symptoms.
Our findings (66 and 65.4% respectively, without gen-
der differences) are similar to those of Yan et al about a
smaller sample of 59 positive patients;10 a recent European
multicenter study reported higher percentages both for
smell and taste disorders, with a female prevalence.12
Since only one study by Mao et al referred to the prev-
alence of chemosensory impairment in Asiatic COVID-19
population (5%),9 our data seem to corroborate the
hypothesis by Lechien et al that western positive patients
(USA and Europe) may be more subject to the develop-
ment of olfactory and gustatory disorders.12
The majority of patients in this study complained of
complete anosmia/ageusia, confirming the observation
that COVID-19 related impairment tends to induce a
severe olfactory and gustatory dysfunction.10,12
Of particular interest is the analysis of the timing of
anosmia: the loss of smell was noted in 54% prior to diag-
nosis and appeared as the first symptom in 13% of cases.
Recent onset of olfactory disorders may drive the physi-
cians to treat these patients as possible COVID-19 positive:
adequate precautions for the health care practitioners,
PCR-testing, and home self-isolation are crucial measures
to avoid that such patients continuing to accidentally act
as vectors of the disease.
Another pivotal issue of the research regards the
recovery of olfactory and gustatory functions: 49.5% of
patients reported a full regaining of both senses after
14 days since the beginning of the symptoms and this
percentage improved to 62.9% at time of interview
(23 days median, range 15-31), with a median recovery
time of 10 days. Obviously, even if our follow- up is lon-
ger than other reports,10-12 it remains too short to give a
conclusive interpretation regarding the prognosis.
FIGURE 2 Daily rate of recovery for both smell (blue) and taste disorders (red) [Color figure can be viewed at wileyonlinelibrary.com]
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Although the exact mechanism with which SARS-
CoV-2 could impair smell and taste has not been defini-
tively determined, two hypotheses appear to be plausible:
damage to the olfactory epithelium, due to cell expression
of angiotensin converting enzyme 2 (ACE2) receptors
which act as a binding point for the virus,16 or a direct
assault on the olfactory neurons.17 The relatively rapid
and spontaneous recovery of most patients in the current
and in other studies, tends to suggest an epithelial based
pathogenesis, given the capability for the epithelium to
quickly restore its functions after damage.10-12
According to some Authors, the presence of 15 vari-
ants of the ACE2 gene explains many ACE2 polymor-
phisms and differences in expression between European
and Asian populations; this finding could be a cue to
investigate if different patterns may influence susceptibil-
ity and clinical features of COVID-19 infection.18
The current study presents some limitations, shared
by all similar researches. First of all, the patients did not
undergo nasal endoscopy, specific imaging or objective smell
assessment; these examinations would contribute to a better
understanding of pathogenetic mechanisms and to define
some prognostic factors about the functional recovery.
Second, the evaluation tool was a self-reported smell
and taste score: It has been previously demonstrated that
subjective evaluation of sense of smell is quite specific
but less sensitive than objective testing.19 Moreover, the
survey was rapidly developed by the Authors with the
aim of collecting and sharing the most possible data in
the shortest time; after such emergency contingency,
additional validation is needed.
Third, even if our population is quite numerous, the
sampling time was short and limited to a single center;
future studies on larger samples can help to clarify the
prevalence of anosmia/ageusia in COVID-19 patients.
Lastly, no patients in this study received specific treat-
ment for olfactory or gustatory loss; currently no medical
treatment has proved to be highly effective in post-viral
anosmia.20-22 The potential risks of immunosuppression
with the use of oral and some topical steroids also need
to be borne in mind, consequently we agree with most
authors, who recommend against specific therapy.4-8,12,13
A different approach could be applied to those
patients with persistent olfactory disorders after complete
recovery from COVID-19 and an exhaustive smell/taste
assessment; in any case, further studies are needed in
order to investigate potential benefits of treatment in
selected cases.
Beyond the limitation, this is one of the first studies
to provide the prevalence, the onset time, the severity
and the recovery time of COVID-19 related smell and
taste disorders; the follow-up time is acceptable and the
sample is various and quite representative: Novara,
indeed, is a small city (100 000 inhabitants) near the
border with the Lombardy Region, the epicenter of the
Italian COVID-19 outbreak; at accrual time—March
30th—the positive patients in the town were almost
800, of which 355 were enrolled in the current research.
The current study strongly confirms the high prevalence
of olfactory and gustatory disorders in COVID-19 infec-
tion.22 Smell and taste loss may be used as indicators of
potential contagion, and early identification may help to
reduce the risk of spread, especially by paucisymptomatic
cases.
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